We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.11% | 35.00 | 34.72 | 35.22 | 35.12 | 34.71 | 34.73 | 970,153 | 22:00:00 |
From Dec 2022 to Dec 2024
By Sabela Ojea
Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment.
At 9:43 a.m. ET, shares were up 21% at $3.83. The stock has, however, dropped 75% in the past 12 months.
The clinical-stage cell and gene therapy company said its early P-BCMA-ALLO1 clinical results inspire it to further develop the treatment for relapsed-refractory multiple myeloma in partnership with Roche.
Last year, Poseida said it signed a strategic collaboration with the biotechnology company Roche.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 11, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
